Mokari Atabak's Form 4 filing
Corcept Therapeutics Inc (CORT) · filed Jun 3, 2026
- Accession no.
- 0001193125-26-256011
- Filed
- Jun 3, 2026
- Trade date
- Jun 1-2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.80M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mokari AtabakCIK 0001678419 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Common Stock | MOption exerciseAcquired | +40,000 | $19.26 | +$770,400 | 55,257 | Direct | |
| Jun 1, 2026 | Common Stock | SSaleDisposed | −40,000 | $70.00F3 | −$2,800,000 | 15,257 | Direct | |
| Jun 1, 2026 | Common Stock | AGrant or awardAcquired | +634 | $70.44F5 | +$44,658.96 | 15,891 | Direct | |
| Jun 1, 2026 | Common Stock | AGrant or awardAcquired | +634 | $0.00 | $0 | 16,525 | Direct | |
| Jun 2, 2026 | Common Stock | FTax withholdingDisposed | −395 | $70.44F8 | −$27,823.8 | 16,130 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | Common Stock | MOption exerciseDisposed | −40,000 | $0.00 | $0 | 60,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $70.00 to $70.01 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Referenced by the price of 1 transaction in Table I.
- F5
In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
Referenced by the price of 1 transaction in Table I.
- F8
The closing price on June 1, 2026 was used to calculate the withholding obligation.
Referenced by the price of 1 transaction in Table I.
Remarks
The power of attorney under which this form was signed is on file with the Commission.